Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis

David A. Folt; Kaleigh L. Evans; Sravya Brahmandam; Wencan He; Pamela S. Brewster; Shipeng Yu; Timothy P. Murphy; Donald E. Cutlip; Lance D. Dworkin; Kenneth Jamerson; William Henrich; Philip A. Kalra; Sheldon Tobe; Ken Thomson; Andrew Holden; Brian L. Rayner; Liliana Grinfeld; Steven T. Haller; Christopher J. Cooper

doi:10.1016/j.jash.2015.03.007

Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis

David A. Folt, Kaleigh L. Evans, Sravya Brahmandam, Wencan He, Pamela S. Brewster, Shipeng Yu, Timothy P. Murphy, Donald E. Cutlip, Lance D. Dworkin, Kenneth Jamerson, William Henrich, Philip A. Kalra, Sheldon Tobe, Ken Thomson, Andrew Holden, Brian L. Rayner, Liliana Grinfeld, Steven T. Haller, Christopher J. Cooper

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti-hypertensive medications (1.9 ± 1.5 vs. 2.4 ± 1.4; P < .001) and were less likely to be treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P<.001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal-artery stenosis. JAm Soc Hypertens 2015;9(6):443-452.

Original language	English (US)
Pages (from-to)	443-452
Number of pages	10
Journal	Journal of the American Society of Hypertension
Volume	9
Issue number	6
DOIs	https://doi.org/10.1016/j.jash.2015.03.007
State	Published - 2015

Keywords

Antihypertensive medical therapy
Geography
Renovascular hypertension

ASJC Scopus subject areas

Internal Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jash.2015.03.007

Fingerprint Dive into the research topics of 'Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis'. Together they form a unique fingerprint.

Cite this

Folt, D. A., Evans, K. L., Brahmandam, S., He, W., Brewster, P. S., Yu, S., Murphy, T. P., Cutlip, D. E., Dworkin, L. D., Jamerson, K., Henrich, W., Kalra, P. A., Tobe, S., Thomson, K., Holden, A., Rayner, B. L., Grinfeld, L., Haller, S. T., & Cooper, C. J. (2015). Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis. Journal of the American Society of Hypertension, 9(6), 443-452. https://doi.org/10.1016/j.jash.2015.03.007

Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis. / Folt, David A.; Evans, Kaleigh L.; Brahmandam, Sravya; He, Wencan; Brewster, Pamela S.; Yu, Shipeng; Murphy, Timothy P.; Cutlip, Donald E.; Dworkin, Lance D.; Jamerson, Kenneth; Henrich, William; Kalra, Philip A.; Tobe, Sheldon; Thomson, Ken; Holden, Andrew; Rayner, Brian L.; Grinfeld, Liliana; Haller, Steven T.; Cooper, Christopher J.

In: Journal of the American Society of Hypertension, Vol. 9, No. 6, 2015, p. 443-452.

Research output: Contribution to journal › Article › peer-review

Folt, DA, Evans, KL, Brahmandam, S, He, W, Brewster, PS, Yu, S, Murphy, TP, Cutlip, DE, Dworkin, LD, Jamerson, K, Henrich, W, Kalra, PA, Tobe, S, Thomson, K, Holden, A, Rayner, BL, Grinfeld, L, Haller, ST & Cooper, CJ 2015, 'Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis', Journal of the American Society of Hypertension, vol. 9, no. 6, pp. 443-452. https://doi.org/10.1016/j.jash.2015.03.007

Folt, David A. ; Evans, Kaleigh L. ; Brahmandam, Sravya ; He, Wencan ; Brewster, Pamela S. ; Yu, Shipeng ; Murphy, Timothy P. ; Cutlip, Donald E. ; Dworkin, Lance D. ; Jamerson, Kenneth ; Henrich, William ; Kalra, Philip A. ; Tobe, Sheldon ; Thomson, Ken ; Holden, Andrew ; Rayner, Brian L. ; Grinfeld, Liliana ; Haller, Steven T. ; Cooper, Christopher J. / Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis. In: Journal of the American Society of Hypertension. 2015 ; Vol. 9, No. 6. pp. 443-452.

@article{099313693d654157b9fd56a2ab1c2996,

title = "Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis",

abstract = "For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti-hypertensive medications (1.9 ± 1.5 vs. 2.4 ± 1.4; P < .001) and were less likely to be treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P<.001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal-artery stenosis. JAm Soc Hypertens 2015;9(6):443-452.",

keywords = "Antihypertensive medical therapy, Geography, Renovascular hypertension",

author = "Folt, {David A.} and Evans, {Kaleigh L.} and Sravya Brahmandam and Wencan He and Brewster, {Pamela S.} and Shipeng Yu and Murphy, {Timothy P.} and Cutlip, {Donald E.} and Dworkin, {Lance D.} and Kenneth Jamerson and William Henrich and Kalra, {Philip A.} and Sheldon Tobe and Ken Thomson and Andrew Holden and Rayner, {Brian L.} and Liliana Grinfeld and Haller, {Steven T.} and Cooper, {Christopher J.}",

note = "Funding Information: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Bethesda, MD) under Award Numbers U01HL072734, U01HL072735, U01HL072736, and U01HL072737. Dr Cooper and Ms Brewster have also received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health ( 5U01HL071556 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drugs for this study were provided by AstraZeneca, device support was provided by Cordis Corporation, and supplemental financial support was granted by both the Cordis Corporation and Pfizer, Inc . Research Article ",

year = "2015",

doi = "10.1016/j.jash.2015.03.007",

language = "English (US)",

volume = "9",

pages = "443--452",

journal = "Journal of the American Society of Hypertension",

issn = "1933-1711",

publisher = "Elsevier Ireland Ltd",

number = "6",

}

TY - JOUR

T1 - Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis

AU - Folt, David A.

AU - Evans, Kaleigh L.

AU - Brahmandam, Sravya

AU - He, Wencan

AU - Brewster, Pamela S.

AU - Yu, Shipeng

AU - Murphy, Timothy P.

AU - Cutlip, Donald E.

AU - Dworkin, Lance D.

AU - Jamerson, Kenneth

AU - Henrich, William

AU - Kalra, Philip A.

AU - Tobe, Sheldon

AU - Thomson, Ken

AU - Holden, Andrew

AU - Rayner, Brian L.

AU - Grinfeld, Liliana

AU - Haller, Steven T.

AU - Cooper, Christopher J.

N1 - Funding Information: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Bethesda, MD) under Award Numbers U01HL072734, U01HL072735, U01HL072736, and U01HL072737. Dr Cooper and Ms Brewster have also received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health ( 5U01HL071556 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drugs for this study were provided by AstraZeneca, device support was provided by Cordis Corporation, and supplemental financial support was granted by both the Cordis Corporation and Pfizer, Inc . Research Article

PY - 2015

Y1 - 2015

N2 - For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti-hypertensive medications (1.9 ± 1.5 vs. 2.4 ± 1.4; P < .001) and were less likely to be treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P<.001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal-artery stenosis. JAm Soc Hypertens 2015;9(6):443-452.

AB - For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti-hypertensive medications (1.9 ± 1.5 vs. 2.4 ± 1.4; P < .001) and were less likely to be treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P<.001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal-artery stenosis. JAm Soc Hypertens 2015;9(6):443-452.

KW - Antihypertensive medical therapy

KW - Geography

KW - Renovascular hypertension

UR - http://www.scopus.com/inward/record.url?scp=84942901706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942901706&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2015.03.007

DO - 10.1016/j.jash.2015.03.007

M3 - Article

C2 - 26051926

AN - SCOPUS:84942901706

VL - 9

SP - 443

EP - 452

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 6

ER -